In a Phase II trial a combination targeted therapy achieved a 51% overall response rate in patients with cholangiocarcinoma and BRAF V600E mutations. This is the first prospective study for this group of patients.
from Health & Medicine News -- ScienceDaily https://www.sciencedaily.com/releases/2020/08/200817191745.htm
No comments:
Post a Comment